Lineage Cell Therapeutics, Inc Stock (NYSEAMERICAN:LCTX)

USA |NYSE MKT |USD

Price
$ 2.16
Change
-2.26%
Today's Range
$2.10 - $2.22
52-Week Range
$1.30 - $3.13
Market Cap
$364.09M
Volume
984.57K

About Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX)

(NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Show more

LCTX Stock Price

Statistics Highlights (NYSEAMERICAN:LCTX)

Shares Outstanding 168.56M Beta 1.70
Public Float 127.38M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders 4.48% Ex-Dividend Date
Held by Institutions 45.15% IPO Date Mar 6, 1992

LCTX Financial Summary

|
Dec 20 Dec 19 Dec 18
Revenue $773.00K $3.52M $4.99M
EBITDA $-19.78M $-15.99M $-43.06M
Net Income $-20.65M $-11.71M $-45.99M
Total Assets $107.95M $125.48M $101.66M
Total Cash $32.59M $9.50M $23.59M
Total Debt $3.83M $5.17M $2.27M
Sep 21 Jun 21 Mar 21
Revenue $2.20M $441.00K $293.00K
EBITDA $-8.64M $-4.75M $-14.04M
Net Income $-7.82M $-4.79M $-1.42M
Total Assets $131.21M $134.75M $127.93M
Total Cash $60.81M $62.00M $56.21M
Total Debt $2.72M $2.90M $3.55M

LCTX Stock Price History

Lineage Cell Therapeutics, Inc Annual Stock Price History

Year Open Close Change
2021 $2.44 $2.16 -11.48%
2021 $1.75 $2.44 39.43%
2020 $0.86 $1.75 103.73%

Lineage Cell Therapeutics, Inc Daily Stock Price History

Date Open High Low Close Change Volume
Jun 10, 2022 $1.44 $1.48 $1.38 $1.40 -6.67% 559.47K
Jun 7, 2022 $1.37 $1.51 $1.36 $1.50 6.38% 1.52M
Jun 21, 2022 $1.36 $1.41 $1.34 $1.41 2.92% 1.03M

(NYSEAMERICAN:LCTX) Stock Price FAQs

What is today's stock price of Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX)?

  • The current stock price of Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX) is $2.16.
  • Today LCTX stock price opened at $2.18 after previous close of $2.21.
  • During the day, Lineage Cell Therapeutics, Inc stock quote has varied from a low of $2.10 to a high of $2.22.

What is Lineage Cell Therapeutics, Inc's 52-week change?

  • LCTX 52-week high stock quote is $3.13, which is 44.90% above the current share price.
  • The Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX) 52-week low stock price is $1.30, which is 39.80% below the current share price.
  • Lineage Cell Therapeutics, Inc share price volatility (52-week beta) is 1.70.

Is Lineage Cell Therapeutics, Inc a buy?

  • According to 5 analysts, the current consensus recommendation for Lineage Cell Therapeutics, Inc stock is "Buy" at an average rating score of 4.20 (out of 5).
  • There are currently 2 "Strong Buy", 2 "Buy", 1 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the LCTX stock.
  • The 12 month average price target forecast for LCTX stock is $6.50, representing a 200.90% increase from the current LCTX stock price of $2.16.

Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX) FAQ

How Much is Lineage cell therapeutics, inc Worth?

Lineage cell therapeutics, inc's worth today based on market capitalisation is $364.09M

How much dividend does Lineage cell therapeutics, inc Pay?

The current annualized dividend payout for LCTX stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Lineage cell therapeutics, inc's "Dividend" Section

When is the next earnings date for Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX)?

Lineage cell therapeutics, inc is expected to report earnings on August 10 ,2022.
View More Details on Lineage cell therapeutics, inc's 'Earnings' Section

What is Lineage cell therapeutics, inc’s Price to Earning (PE) ratio?

LCTX stock also has a Price to Sales (P/S) ratio of 103.20.

What is the Lineage cell therapeutics, inc's ticker?

Lineage cell therapeutics, inc trades on the NYSE American stock market in USA under the ticker symbol "LCTX". Lineage cell therapeutics, inc’s stock symbol can also be displayed as "NYSEAMERICAN:LCTX".

When did LCTX go public?

Lineage cell therapeutics, inc completed its initial public offering (IPO) on March 06 ,1992.

Who are the owners of Lineage cell therapeutics, inc?

Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX) is owned by 45.15% institutional shareholders and by 4.48% insiders. The rest is owned by the public.
Explore More Details on Lineage cell therapeutics, inc's “Ownership” Section

Who are the key executives of Lineage cell therapeutics, inc (LCTX)?

Lineage cell therapeutics, inc's key executive team includes the following managers:

  • Mr. Brian M. Culley M.A., M.B.A., CEO, Pres & Director (1971)
  • Ms. Brandi L. Roberts, Consultant (1974)
  • Mr. Kevin L. Cook, Chief Financial Officer (1971)
  • Ioana C. Hone, Director of Investor Relations (NA)
  • Mr. George A. Samuel III, J.D., Gen. Counsel & Company Sec. (NA)
  • Dr. François Binette M.Sc., Ph.D., Sr. VP & Global Head of R&D (NA)
  • Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D., Sr. VP of Clinical & Medical Affairs (1968)
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (1954)
  • Dr. Rami Skaliter, Chief Exec. Officer of Cell Cure Neurosciences Ltd. (1958)
  • Ms. Alexandra Hernandez, Sr. Director of Fin. & Controller (NA)

What is Lineage cell therapeutics, inc’s Sector & Industry Classification?

Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Lineage cell therapeutics, inc?

Currently the number of employees working for Lineage cell therapeutics, inc is 49.

Where are Lineage cell therapeutics, inc's Headquarters?

Lineage cell therapeutics, inc (NYSEAMERICAN:LCTX) is headquartered in CA, United States.

What are Lineage cell therapeutics, inc's Address and Phone Number?

Lineage cell therapeutics, inc’s mailing address is 2173 Salk Avenue, Carlsbad, CA, United States, 92008.
The company’s phone number is 442 287 8990.

What is the official website for Lineage cell therapeutics, inc?

Lineage cell therapeutics, inc’s official website is http://www.lineagecell.com